Literature DB >> 2729631

Pancuronium, gallamine, and d-tubocurarine compared: is speed of onset inversely related to drug potency?

A F Kopman1.   

Abstract

The relative potency and speed of onset of action of pancuronium, gallamine, and d-tubocurarine was studied in 55 adult female patients receiving nitrous oxide/oxygen-narcotic anesthesia. The integrated electromyogram of the adductor pollicis muscle was monitored using a cumulative dose-response technique; train-of-four stimuli were administered at 0.05 Hz. The measured ED95 values for pancuronium and gallamine were 0.069 and 2.38 mg/kg, respectively. In three separate groups, pancuronium 0.07 mg/kg, gallamine 2.4 mg/kg, or d-tubocurarine 0.45 mg/kg were given as a single bolus and the speed of onset and time to maximum effect determined. Peak twitch depression was essentially identical in all groups (92.7 +/- 1.4 [SE] vs. 93.3 +/- 1.1 vs. 93.7 +/- 1.1%, respectively). The rate of onset of neuromuscular blockade in these three groups was, however, quite different. After administration of pancuronium (n = 10) the times to 5%, 20%, 50%, and 80% twitch depression were 68 +/- 5, 97 +/- 6, 141 +/- 8, and 222 +/- 18 s. The comparable times following gallamine (n = 10) were 29 +/- 2, 42 +/- 3, 66 +/- 5, and 136 +/- 14 s; d-tubocurarine (n = 10) was intermediate in speed with onset times of 40 +/- 4, 63 +/- 6, 99 +/- 11, and 178 +/- 25 s. It appears that the onset times of different nondepolarizing blocking agents (even when given in equipotent doses) may vary by clinically appreciable amounts. The results of this study support the hypothesis that nondepolarizing neuromuscular blocking agents of low potency may have a more rapid onset of action than that seen with agents of high potency.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2729631

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  14 in total

Review 1.  Rapacuronium bromide: a review of its use in anaesthetic practice.

Authors:  S V Onrust; R H Foster
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

2.  A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.

Authors:  F Donati; C Meistelman
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

3.  Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats.

Authors:  K Yamamoto; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

4.  An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs.

Authors:  J H Proost; J M Wierda; D K Meijer
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

Review 5.  Clinical pharmacokinetics of cisatracurium besilate.

Authors:  D F Kisor; V D Schmith
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

6.  Simulation of the kinetics of neuromuscular block: implications for speed of onset.

Authors:  James P Dilger
Journal:  Anesth Analg       Date:  2013-03-01       Impact factor: 5.108

7.  Rocuronium (ORG 9426) neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis in humans.

Authors:  C Meistelman; B Plaud; F Donati
Journal:  Can J Anaesth       Date:  1992-09       Impact factor: 5.063

8.  Pharmacodynamic behaviour of rocuronium in the elderly.

Authors:  D R Bevan; P Fiset; P Balendran; J C Law-Min; A Ratcliffe; F Donati
Journal:  Can J Anaesth       Date:  1993-02       Impact factor: 5.063

9.  In vitro potency and mode of action of ANQ9040: a novel fast acting muscle relaxant.

Authors:  G Lees; I T Munday; M D Edwards; R M Jones
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

10.  Clinical pharmacology of ORG 7617, a short-acting non-depolarizing neuromuscular blocking agent.

Authors:  L van den Broek; J M Wierda; J H Proost; F D Hommes; S Agoston
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.